Pharmaceutical Giants Merck and Pfizer Underperform as Market Shifts

While equity indices climbed on optimistic earnings reports, two of the world’s largest pharmaceutical manufacturers continued to underperform the broader market. Merck’s shares retreated by 1% and Pfizer fell nearly 5%, bucking the upward trend that saw the S&P 500 and Nasdaq advance. This divergence reflects a deeper realignment within the healthcare sector as investors reassess which companies are best positioned to navigate the coming decade’s challenges.

Earnings Divergence: Why Pharma Stocks Lagged Behind Market Rally

The tech and gold sectors captured investor enthusiasm while the pharmaceutical giants struggled to maintain momentum. Despite delivering earnings results that were respectable if not remarkable, Merck and Pfizer found themselves trailing the broader index. This underperformance signals investor concern about the industry’s exposure to patent expirations, pricing pressures, and the near-term earnings outlook as blockbuster drugs lose their exclusivity windows.

Merck’s Oncology Dominance and the Pipeline Challenge

Merck demonstrated solid operational performance, posting 5% global sales growth in Q4 to reach $16.4 billion (4% adjusted for currency impacts), with full-year revenue exceeding $65 billion. The company’s oncology franchise remains its commercial pillar, with Keytruda—its flagship cancer immunotherapy—generating nearly $32 billion annually, representing almost half of total company revenue. This reliance on a single product, however, introduces strategic vulnerability as the drug approaches the end of its patent protection window in the latter half of the decade.

To mitigate future revenue headwinds, Merck has been expanding its newer therapeutic offerings. The hypertension drug Winrevair achieved $1.4 billion in first-year sales, while the pneumococcal vaccine Capvaxix contributed approximately $800 million. The Animal Health division also showed strength, with sales climbing 8% to $6.4 billion. For 2026, management guidance points to revenue stabilizing around $66 billion, suggesting confidence that emerging products will help offset anticipated Keytruda declines.

Pfizer’s Strategic Positioning Amid Patent Pressures

Pfizer reported full-year 2025 revenue of approximately $63 billion, down 2% year-over-year, reflecting the cumulative impact of patent losses and market competition. The company’s oncology segment proved resilient, with newer agents like Padcev and Lorbrena helping to limit overall decline rates. On a brighter note, adjusted earnings per share climbed 4% to $3.22, powered by operational efficiencies and improved cost management.

For 2026, Pfizer reiterated its revenue guidance between $59.5 billion and $62.5 billion, with adjusted EPS expected to range from $2.80 to $3.00. While these projections suggest continued top-line pressure, management has outlined an aggressive development agenda, with approximately 20 pivotal clinical trials slated to initiate this year. This robust pipeline represents the company’s primary lever for reigniting growth and justifying premium valuations against underperforming near-term metrics.

Industry Outlook: Navigating Exclusivity Losses

The divergent trajectories of Merck and Pfizer illustrate a broader industry tension: mature portfolios anchored to blockbuster franchises are increasingly vulnerable to patent cliffs, while companies with diversified pipelines and emerging product successes command investor confidence. Large pharmaceutical firms continue to demonstrate operational resilience and strategic adaptability, but the market’s willingness to look past current underperformance depends critically on whether development pipelines can deliver meaningful late-stage victories. The coming years will separate winners from laggards within the sector.